文献速递脑血管病

急性缺血性卒中发病4.5小时内静脉注射重组人尿激酶原的安全性和有效性(PROST-2):一项3期、开放标签、非劣效性、随机对照试验

Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
PubMed 文献 · Lancet Neurol · 2024-11-29

PROST-2是一项在中国61家医院进行的3期、开放标签、非劣效性随机对照试验,纳入发病4.5小时内、不适合或拒绝血管内取栓的急性缺血性卒中患者。重组人尿激酶原组90天改良Rankin量表评分0或1分的比例为72.0%,阿替普酶组为68.7%(风险比1.04 [95% CI 0.98至1.10];非劣效性p<0.0001)。重组人尿激酶原组36小时内症状性颅内出血发生率低于阿替普酶组(0.3% vs 1.3%)。

要点

  • 重组人尿激酶原在90天良好功能结局方面非劣效于阿替普酶。
  • 重组人尿激酶原组症状性颅内出血和大出血发生率低于阿替普酶组。
  • 两组7天内全因死亡率无显著差异。

核心结论

  • 在本试验中,重组人尿激酶原在实现优良功能结局方面非劣效于阿替普酶,且两组安全性终点无差异。
  • 这些发现支持将重组人尿激酶原作为阿替普酶的可行替代方案,用于适合静脉溶栓治疗但不适合或拒绝血管内取栓的缺血性卒中患者。

研究设计与样本

  • PROST-2是一项3期、开放标签、非劣效性、随机对照试验,在中国61家医院进行。
  • 纳入年龄大于18岁、发病4.5小时内、不适合或拒绝血管内取栓的急性缺血性卒中患者,按1:1比例随机分配。
  • 重组人尿激酶原组给予15 mg团注后30分钟内输注20 mg;阿替普酶组给予0.9 mg/kg(最大剂量90 mg),10%团注后剩余剂量60分钟内输注。
  • 主要疗效结局为90天改良Rankin量表评分0或1分的患者比例,在意向治疗人群中通过盲法评估,风险比非劣效性界值为0.93。
  • 主要安全性结局为36小时内症状性颅内出血发生率。

主要发现

  • 90天改良Rankin量表评分0或1分:重组人尿激酶原组558/775例(72.0%)vs 阿替普酶组534/777例(68.7%),风险比1.04(95% CI 0.98至1.10),非劣效性p<0.0001。
  • 36小时内症状性颅内出血:重组人尿激酶原组2/770例(0.3%)vs 阿替普酶组10/775例(1.3%),风险差-1.0个百分点(95% CI -2.1至-0.1),p=0.021。
  • 7天内大出血:重组人尿激酶原组4/775例(0.5%)vs 阿替普酶组16/775例(2.1%),风险差-1.5个百分点(95% CI -2.8至-0.4),p=0.0072。
  • 7天内全因死亡:重组人尿激酶原组5/775例(0.6%)vs 阿替普酶组13/775例(1.7%),风险差-1.0个百分点(95% CI -2.3至0.1),p=0.060。

关键数值与推荐

  • 非劣效性界值:风险比0.93。
  • 重组人尿激酶原剂量方案:15 mg团注后30分钟内输注20 mg。
  • 阿替普酶剂量方案:0.9 mg/kg(最大剂量90 mg),10%团注后剩余剂量60分钟内输注。

临床怎么用

  • 作者认为,重组人尿激酶原可作为阿替普酶的可行替代方案,用于适合静脉溶栓治疗但不适合或拒绝血管内取栓的缺血性卒中患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy. METHODS: PROST-2 was a phase 3, open-label, non-inferiority, randomised controlled trial conducted at 61 hospitals in China. Patients older than 18 years with acute ischaemic stroke, who were ineligible for or who refused endovascular thrombectomy, were randomly assigned in a 1:1 ratio within 4·5 h of stroke onset to receive intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min) or intravenous alteplase (0·9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min). The primary efficacy outcome was the proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days, assessed via masked review in the intention-to-treat population, with a non-inferiority margin for the risk ratio of 0·93. The primary safety outcome was the incidence of symptomatic intracranial haemorrhage within 36 h. This trial is registered with ClinicalTrials.gov (NCT05700591) and is now completed. FINDINGS: Between Jan 29, 2023, and March 14, 2024, 1552 patients were randomly assigned: 775 received recombinant human prourokinase and 777 received alteplase. The primary outcome of a modified Rankin Scale score of 0 or 1 at 90 days was reached by 558 (72·0%) of 775 patients in the recombinant human prourokinase group versus 534 (68·7%) of 777 in the alteplase group (risk ratio 1·04 [95% CI 0·98 to 1·10]; p<0·0001 for non-inferiority). The frequency of symptomatic intracranial haemorrhage within 36 h was lower in the recombinant human prourokinase group than in the alteplase group (two [0·3%] of 770 patients vs ten [1·3%] of 775, risk difference -1·0 percentage points [95% CI -2·1 to -0·1]; p=0·021), as was the incidence of major bleeding at 7 days (four [0·5%] vs 16 [2·1%]; -1·5 percentage points (-2·8 to -0·4); p=0·0072). All-cause mortality within 7 days did not differ between groups (five [0·6%] deaths in the recombinant human prourokinase group vs 13 [1·7%] in the alteplase group; risk difference -1·0 percentage points; 95% CI -2·3 to 0·1]; p=0·060). INTERPRETATION: In our trial, recombinant human prourokinase was shown to be non-inferior to alteplase for achieving excellent functional outcome, with no difference between groups in safety endpoints. These findings support the use of recombinant human prourokinase as a viable alternative to alteplase for patients with ischaemic stroke who are eligible for intravenous thrombolysis therapy but ineligible for or who have refused endovascular thrombectomy. FUNDING: Tasly Biopharmaceuticals, National Key R&D Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, and Beijing Municipal Science & Technology Commission. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Li S, Gu HQ, Feng B, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. Lancet Neurol. 2024. PMID: 39617030. doi:10.1016/S1474-4422(24)00436-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。